{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:53:56Z","timestamp":1790096036995,"version":"4.0.1"},"reference-count":23,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, providing substantial survival benefits across a wide range of malignancies. However, ICI-associated renal toxicity encompasses a broad spectrum of clinical entities, ranging from nonspecific acute kidney injury to well-defined immune-mediated nephropathies with distinct pathophysiological mechanisms. Methods: We performed a large-scale pharmacovigilance study using the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluate immune-mediated nephropathy associated with ICIs from January 2014 to March 2025. To improve specificity and minimize misclassification, the analysis was restricted to well-defined immune-mediated renal adverse events identified using MedDRA Preferred Terms, excluding nonspecific acute kidney injury. Disproportionality analysis was conducted using reporting odds ratios (RORs) with 95% confidence intervals (CIs) to assess associations between individual ICIs, treatment regimens, and nephropathy reporting. Results: Among 203,652 ICI-related adverse event reports (irAEs), 2361 (1.12%) involved immune-mediated nephropathy. Compared with other irAEs (non-nephropathy), immune-mediated nephropathy was more frequently reported in patients aged \u2265 65 years and in those with lung and genitourinary malignancies. Tubulointerstitial nephritis was the predominant subtype. Higher reporting signals were observed with cemiplimab and pembrolizumab, whereas durvalumab and atezolizumab demonstrated lower reporting signals. Combination regimens involving PD-1 and CTLA-4 inhibitors were associated with higher reporting frequencies compared with monotherapy. Conclusions: This real-world pharmacovigilance analysis identifies clinically relevant differences in immune-mediated nephropathy reporting across ICI classes and treatment strategies. PD-1 inhibitors and PD-1\/CTLA-4 combination regimens were associated with higher reporting signals, suggesting potential variation in renal safety profiles. These findings should be interpreted cautiously, given the inherent limitations of spontaneous reporting systems, but they provide hypothesis-generating evidence to support future prospective studies with detailed clinical and histopathological correlation.<\/jats:p>","DOI":"10.3390\/jcm15103812","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:19:29Z","timestamp":1778854769000},"page":"3812","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Immune Checkpoint Inhibitor-Associated Immune-Mediated Nephropathy: A Real-World Pharmacovigilance Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7701-3713","authenticated-orcid":false,"given":"Aydan","family":"Mutis Alan","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpa\u015fa, Istanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1948-2914","authenticated-orcid":false,"given":"Ahmet","family":"Murt","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpa\u015fa, Istanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mevl\u00fct Tamer","family":"Din\u00e7er","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpa\u015fa, Istanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3843-5950","authenticated-orcid":false,"given":"Sinan","family":"Trabulus","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpa\u015fa, Istanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-2012","authenticated-orcid":false,"given":"\u00d6zkan","family":"Alan","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpa\u015fa, Istanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet R\u0131za","family":"Altiparmak","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpa\u015fa, Istanbul 34098, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Catalano, M., Roviello, G., Galli, I.C., Santi, R., and Nesi, G. (2022). Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1014257"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/ckj\/sfab052","article-title":"Checkpoint inhibitor therapy-associated acute kidney injury: Time to move on to evidence-based recommendations","volume":"14","author":"Perazella","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Kumar, V., Chaudhary, N., Garg, M., Floudas, C.S., Soni, P., and Chandra, A.B. (2017). Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Front. Pharmacol., 8, Erratum in Front. Pharmacol. 2017, 8, 311. https:\/\/doi.org\/10.3389\/fphar.2017.00311.","DOI":"10.3389\/fphar.2017.00049"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.37047\/jos.galenos.2024.2024.104195","article-title":"Neurotoxicity in the Era of Immune Checkpoint Inhibitors: A Case-Based Approach","volume":"11","author":"Alan","year":"2025","journal-title":"J. Oncol. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/ndt\/gfae184","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2025, June 18). FDA Adverse Event Reporting System (FAERS) Public Dashboard, Available online: https:\/\/fis.fda.gov\/sense\/app\/95239e26-e0be-42d9-a960-9a5f7f1c25ee\/sheet\/7a47a261-d58b-4203-a8aa-6d3021737452\/state\/analysis."},{"key":"ref_9","unstructured":"(2025, June 18). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Medical Dictionary for Regulatory Activities (MedDRA) Version 28.0. Available online: https:\/\/www.meddra.org\/."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Xu, L.Y., Zhao, H.Y., Yu, X.J., Wang, J.W., Zheng, X.Z., Jiang, L., Wang, S.X., Liu, G., and Yang, L. (2023). Clinicopathological Features of Kidney Injury Related to Immune Checkpoint Inhibitors: A Systematic Review. J. Clin. Med., 12.","DOI":"10.3390\/jcm12041349"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, C., Wei, W., Yang, L., Li, J., Yi, C., Pu, Y., Yin, T., Na, F., Zhang, L., and Fu, P. (2023). Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1173952"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1620\/tjem.254.275","article-title":"Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020","volume":"254","author":"Qu","year":"2021","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/cac2.12396","article-title":"Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Koks, M.S., Ocak, G., Suelmann, B.B.M., Hulsbergen-Veelken, C.A.R., Haitjema, S., Vianen, M.E., Verhaar, M.C., Kaasjager, K.A.H., and Khairoun, M. (2021). Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0252978"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2217\/fon-2020-1222","article-title":"Immune-related adverse events with PD-1 versus PD-L1 inhibitors: A meta-analysis of 8730 patients from clinical trials","volume":"17","author":"Sonpavde","year":"2021","journal-title":"Future Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s00262-024-03869-1","article-title":"Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: A retrospective cohort study in patients with advanced cancer","volume":"74","author":"Ladjevardi","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/s41416-022-02084-y","article-title":"Evolving landscape of PD-L2: Bring new light to checkpoint immunotherapy","volume":"128","author":"Wang","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000531297","article-title":"Immune Checkpoint Inhibitor-Associated Nephrotoxicity","volume":"148","author":"Mamlouk","year":"2024","journal-title":"Nephron"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: Single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/ndt\/gfab187","article-title":"Nephrotoxicity of immune checkpoint inhibitor therapy: A pharmacovigilance study","volume":"37","author":"Haeuser","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration\u2019s Adverse Event Reporting System (FAERS): Analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"2014","journal-title":"Drug Saf."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1111\/bcp.14342","article-title":"Reporting rates of adverse reactions to specialty care medicines exhibit a direct positive correlation with patient exposure: A lack of evidence for the Weber effect","volume":"86","author":"Modgill","year":"2020","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3812\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:34:09Z","timestamp":1778855649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/10\/3812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":23,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["jcm15103812"],"URL":"https:\/\/doi.org\/10.3390\/jcm15103812","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}